Dihydropyrimidine Dehydrogenase Activity in Human Peripheral Blood Mononuclear Cells and Liver: Population Characteristics, Newly Identified Deficient Patients, and Clinical Implication in 5-Fluorouracil Chemotherapy

Cancer Research

Volumn 53, Issue 22, 1993, Pages 5433-5438

  Lu, Zhihong ^a   Zhang, Ruiwen ^a   Diasio, Robert B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; LIVER ENZYME; METHOTREXATE; OXIDOREDUCTASE; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; DRUG FATALITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOBLOTTING; LIVER CYTOSOL; MALE; MASS SCREENING; MONONUCLEAR CELL; MUCOSA INFLAMMATION; NEUROPATHY; NORMAL HUMAN; PRIORITY JOURNAL; RECTUM CANCER;

ADULT; AGED; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMAN; LIVER; MALE; MIDDLE AGE; OXIDOREDUCTASES; RECTAL NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027426408     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chabner, B.A., and Myers, C.E. Clinical pharmacology of cancer chemotherapy. In: V.T. DeVita, S. Hellman, and S.A. Rosenberg (eds.), Cancer-Principles and Practice of Oncology, Ed. 3, pp. 349-395. Philadelphia: J.B. Lippincott Company, 1989.
2. Grem, J.L. Fluorinated pyrimidines. In: B.A. Chabner and J.M. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 180-224. Philadelphia: J.B. Lippincott Company, 1990.
3. Diasio, R.B., and Harris, B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
4. Daher, G.C., Harris, B.E., and Diasio, R.B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther., 48: 189-222, 1990.
5. Heggie, G.D., Sommadossi, J.R., Cross, D.S., Huster, W.J., and Diasio, R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
6. Iigo, M., Araki, E., Nakajima, Y., Hoshi, A., and de Clercq, E. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice: increased therapeutic index and correlation with increased plasma 5-fluorouracil level. Biochem. Pharmacol., 37: 1609-1613, 1988.
7. Harris, B.E., Song, R., Soong, Sj., and Diasio, R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
8. Fleming, R.A., Milano, G., Thyss, A., Etienne, M.C., Renee, N., Schneider, M., and Demard, F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res., 52: 2899-2902, 1992.
9. Goldberg, J.A., Kerr, D.J., Willmott, N., McKillop, J.H., and McArdle, C.S. Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil (5-FU) in advanced colorectal liver metastases. Br. J. Cancer, 57: 186-189, 1988.
10. Daher, G.C., Harris, B.E., Zhang, R., Willard, E.M., Soong, Sj., and Diasio, R.B. The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dThdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd) following infusion of FUra or FdUrd. Annu. Rev. Chronopharmacol., 7: 227-230, 1990.
11. Harris, B.E., Song, R., He, Y.J., Soong, Sj., and Diasio, R.B. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase, possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol., 37: 4759-4762, 1988.
12. Harris, B.E., Song, R., Soong, Sj., and Diasio, R.B. Circadian variation of 5-fluorouracil catabolism in isolated perfused liver. Cancer Res., 49: 6610-6614, 1989.
13. Daher, G.C., Zhang, R., Soong, Sj., and Diasio, R.B. Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy. Drug Metab. Dispos., 19: 285-287, 1991.
14. Zhang, R., Lu, Z., Liu, T., Soong, Sj., and Diasio, R.B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res., 53: 2816-2822, 1993.
15. Martin, D.S., Nayak, P., Sawyer, R.C., Stolfi, R.L., Young, C.W., Woodcock, T., and Spiegelman, S. Enhancement of 5-fluorouracil chemotherapy with emphasis on the use of excess thymidine. Cancer Bull. (Houst.), 30: 219-224, 1978.
16. Wasternack, C. Degradation of pyrimidines and pyrimidine analogs-pathways and mutual influences. Pharmacol. Ther., 8: 629-665, 1980.
17. Daher, G.C., Naguib, F.N.M., el Kouni, M.H., Zhang, R., Soong, Sj., and Diasio, R.B. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochem. Pharmacol., 41: 1887-1893, 1991.
18. Porter, D.J.T., Chestnut, W.G., Taylor, L.C.E., Merrill, B.M., and Spector, T. Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil. J. Biol. Chem., 266: 19988-19994, 1991.
19. Diasio, R.B., Beavers, T.L., and Carpenter, J.T. Familial deficiency of dihydropyrimidine dehydrogenase. J. Clin. Invest., 81: 47-51, 1988.
20. Harris, B.E., Carpenter, J.T., and Diasio, R.B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer (Phila.), 68: 499-501, 1991.
21. Lyss, A.P., Lilenbaum, R.C., Harries, B.E., and Diasio, R.B. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest., 11: 239-240, 1993.
22. Tuchman, M., Stoeckeler, J.S., Kiang, D.T., O'Dea, R.F., Rammaraine, M.L., and Mirkin, B.L. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med., 313: 245-249, 1985.
23. Fleming, R.A., Milano, G.A., Gaspard, M.H., Bargnoux, P.J., Thyss, A., Plagne, R., Renee, N., Schneider, M., and Demard, F. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur. J. Cancer, 29A: 740-744, 1993.
24. Shiotani, T., and Weber, G. Purification and properties of dihydrothymine dehydrogenase from rat liver. J. Biol. Chem., 256: 219-224, 1981.
25. Fujimoto, S., Matsuda, K., Kikugama, M., Kaneko, M., and Tamak, N. Effect of vitamin B2 deficiency on rat liver dihydropyrimidine dehydrogenase activity. J. Nutr. Sci. Vitaminol., 37: 89-98, 1991.
26. Podschun, B., Wahler, G., and Schnackerz, K.D. Purification of dihydropyrimidine dehydrogenase from pig liver. Eur. J. Biochem., 185: 219-224, 1989.
27. Naguib, F.N.M., el Kouni, M.H., and Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res., 45: 5405-5412, 1985.
28. Lu, Z., Zhang, R., and Diasio, R.B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem., 267: 17102-17109, 1992.
29. Lu, Z., Zhang, R., and Diasio, R.B. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig, and cow liver. Biochemical and immunological properties. Biochem. Pharmacol., 46: 945-952, 1993.
30. Sommadossi, J.P., Gewirtz, D.A., Diasio, R.B., Aubert, C., Cano, J.P., and Goldman, I.D. Rapid catabolism of 5-fluorouracil in freshly isolated hepatocytes as analyzed by high performance liquid chromatography. J. Biol. Chem., 257: 8171-8176, 1982.
31. Bradford, M.A. Rapid sensitive method for the quantitation of microgram qualities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72; 258-254, 1976.
32. Towbin, H., Staehelin, T., and Gorden, J. Electrophoretic of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
33. Milano, G., Etienne, M.C., Casssuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M., and Demard, F. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol., 10: 1171-1175.
34. Ho, D.H., Townsend, L., Luma, M.A., and Bodely, G.P. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res., 6: 781-784, 1986.
35. Desgranges, C., Razaka, G., De Clercq, E., Herdewijn, P., Balzarini, J., Drouillet, F., and Bricaud, H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res., 46: 1094-1101, 1986.
36. Masaaki, I., Araki, E., Nakajima, Y., and De Clercq, E. Enhancing effects of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. Biochem. Pharmacol., 37: 1609-1613, 1988.
37. Naguib, F.N.M., el Kouni, M.H., and Cha, S. Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver. Biochem. Pharmacol., 38: 1471-1480, 1989.